Analytical Data
-
基因名
DFNA5
- Application
-
别名
ICERE-1; Non-Syndromic Hearing Impairment Protein 5; Inversely correlated with estrogen receptor expression 1
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Z2D3
-
表达区间
Met1~Asp512
-
分子量
60kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DFNA5 is a gene that has garnered significant attention due to its association with hereditary hearing loss, particularly in the context of non-syndromic auditory dysfunction. Mutations in DFNA5 can lead to progressive sensorineural hearing loss, making it crucial for understanding the molecular mechanisms underlying auditory pathways. Research has demonstrated that DFNA5 encodes a protein involved in cellular stress responses, particularly in the inner ear's hair cells, which are essential for sound transduction. The DFNA5 protein may interact with various cellular pathways, including those regulating apoptosis and inflammation, hinting at its potential role in maintaining cellular homeostasis within auditory structures. Moreover, the study of its recombinant protein has opened avenues for exploring therapeutic interventions, as understanding its structure and function could lead to targeted strategies to mitigate hearing loss associated with DFNA5 mutations. Recent advancements in gene therapy and molecular biology techniques further enhance the feasibility of developing effective treatments, making DFNA5 a focal point in auditory research and a promising target for future studies aimed at preventing or reversing hearing impairments linked to genetic factors. Overall, investigations into DFNA5 and its recombinant protein have the potential to considerably advance our understanding of hereditary hearing loss, offering insights that could translate into clinical applications for affected individuals.












